On November 13, Twist Bioscience Corp fell 6.3% in Regular Trading, trading at $108.0 per share, with turnover of $9.1308 million.
The move followed continued pressure after the company’s latest outlook pointed to slower AI drug discovery growth, while several brokerages cut price targets, reinforcing a weaker post-earnings tone.
Twist Bioscience Corp reported fiscal Q4 loss of $0.32 per share on revenue of $126.6 million, both better than consensus, and guided fiscal Q1 revenue to $130 million-$132 million and fiscal revenue to $550 million-$560 million, both slightly above expectations. However, investors focused on signs of decelerating growth in AI drug discovery. Subsequent analyst actions included price-target cuts to $125 from $150, to $150 from $205, and to $150 from $212, even as some firms maintained positive ratings.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments